低用量アトロピンを用いた間欠性外斜視の制御
Farzaneh Dehghanian Nasrabadi1, Ali Mirzajani1, Mostafa Soltan Sanjari2
1Rehabilitation Research Center, Department of Optometry, Iran University of Medical Sciences, Tehran, Iran.
Clinical & experimental optometry
|February 24, 2026
まとめ
低用量アトロピン点眼薬は、小児の間欠性外斜視を効果的に制御し、過矯正レンズと同様の結果を示した。これにより、0.05%アトロピンは、この状態を管理するための実行可能な代替治療選択肢となる。
科学分野:
- 眼科学
- 小児眼科
- 斜視管理
背景:
- 間欠性外斜視には、効果的な非外科的管理戦略が必要である。
- 患者ケアには、最小限のリスクと副作用を持つ治療法の特定が重要である。
研究 の 目的:
- 小児の間欠性外斜視の制御における0.05%アトロピン点眼薬の効果を評価すること。
- 低用量アトロピンと過矯正レンズの効果を比較すること。
主な方法:
- 間欠性外斜視の小児(2〜8歳)を対象としたランダム化臨床試験。
- 参加者は、3ヶ月間0.05%アトロピンまたは過矯正レンズのいずれかに割り当てられた。
- ずれの制御は、3点および6点スケールを用いて評価された。
主要な成果:
- 0.05%アトロピンと過矯正レンズの両方で、介入後1ヶ月および3ヶ月でずれの制御が大幅に改善した。
- 遠方および近方のずれの制御の改善が、両群ともに3ヶ月間にわたって観察された。
- 低用量アトロピンは、3ヶ月で1ヶ月と比較して近方のずれの制御において有意な改善を示した。
結論:
- 低用量アトロピン点眼薬は、小児の間欠性外斜視の制御に効果的である。
- 低用量アトロピンは、過矯正レンズと同等の効果を示す。
- アトロピンは、間欠性外斜視の実行可能な代替治療法となる可能性がある。
関連する概念動画
Open Angle Glaucoma: Treatment
1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Angle Closure Glaucoma: Treatment
1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K
Ophthalmic Drug Delivery Systems
95
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
95
Cholinergic Antagonists: Therapeutic Uses
1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K


